Global Peptide Therapeutics Market to be Fueled by Increasing Prevalence of Cancer and Diabetes

Transparency Market 

Research 

Peptide Therapeutics Market - Global Industry Analysis, Size, Share, 

Growth, Trends and Forecast 2014 – 2020 

Published Date 

2015-04-27 

104 Page Report 

Buy Now 

Request Sample 

Press Release 

Global Peptide Therapeutics Market to be Fueled by Increasing Prevalence 

of Cancer and Diabetes 

Transparency Market Research 

State Tower, 

90, State Street, Suite 700. 

Albany, NY 12207 

United States 

www.transparencymarketresearch.com 

sales@transparencymarketresearch.com

Peptide Therapeutics Market 

REPORT DESCRIPTION 

The global market for peptide therapeutics market derives much of its demand from the treatment of cancer and diabetes. 

The rising incidence of these diseases is making way for the advancement of peptide drugs, which in turn is propelling the 

global peptide therapeutics market. Additionally, the technical advancements in peptide drugs have resulted in a reduction 

in total production cost, fueling the production process of new peptide drugs. 

Browse Full Global Peptide Therapeutics Market Report With Complete TOC @ 

http://www.transparencymarketresearch.com/peptide-therapeutics-market.html 

On the other hand, API manufacturers are facing a tough challenge from the complex structure of peptides. Other than 

this, the lack of regulatory standards to arbitrate developments in peptide drugs is also hampering the growth of the 

peptide therapeutics market. However, biotech enterprises are identifying prospects for future growth in collaboration with 

major pharmaceutical firms across the globe.The global peptide therapeutics market is expected to expand at a CAGR of 

2.8% during the period from 2014 to 2020 in order to reach US$23.7 billion by 2020. The market had reached a value of 

US$18.9 billion in 2013. 

Market for Respiratory Disorders Poised to Grow at Highest CAGR between 2014 and 2020 

Peptide therapeutics find application in the treatment of various kinds of ailments such as cardiovascular, nervous, 

gastrointestinal, respiratory, metabolism-related, in addition to cancer, various infections, and pain. The cancer market was 

the dominant application segment of the peptide therapeutics market in 2013. However, the respiratory disorder market 

segment is projected to develop at the highest CAGR during the period from 2014 to 2020 owing to the recent approval of 

lucinactant, sold under the brand name Surfaxin. 

The global peptide therapeutics market is analyzed on three fronts: Route of administration, marketing status, and regional 

distribution of the global industry. Based on route of administration, parenteral and oral are the two segments of this 

market, while branded peptide therapeutics and generic peptide therapeutics are the segments of the global market on the 

basis of marketing status. The market for generic peptides is expected to do well in the next few years on account of 

patent expirations expected in the branded peptide market in the near future. 

Asia Pacific to Report Highest Compound Annual Growth Rate from 2014 to 2020 


2


Regionally, the global peptide therapeutics market is distributed among North America, Europe, Asia Pacific, and the Rest 

of the World, wherein the global market is dominated by the North American and European markets, which jointly occupy 

over 60% of the global market. However, in spite of the dominance of these regions in the global market, the peptide 

therapeutics market in Asia Pacific is poised to grow at the highest CAGR during the period from 2014 to 2020.The 

peptide therapeutics market in Asia Pacific is majorly driven by the rapid growth of this market in China, India, and Japan. 

The rise in economic stability and increased awareness pertaining to the treatment of various diseases are the major 

factors fueling the growth of the market in this region. 

Browse Full Press Release Report: http://www.transparencymarketresearch.com/pressrelease/peptide-therapeuticsmarket.htm 

Japan is the second largest market in the global individual pharmaceutical industry, whereas China and India have a huge 

population pool suffering from various diseases and ailments that are cured with the help of peptide therapeutics. These 

factors are expected to establish Asia Pacific as the most promising market for peptide therapeutics in the near future. 

China and India are also emerging as some of the largest peptide API suppliers in the world. 

Amgen, Inc., Bachem Holding AG, AstraZeneca Plc, CordenPharma Int. GmbH, Ipsen S.A., Eli Lilly and Co., Lonza 

Group Ltd., Novartis AG, Merck & Co., Inc., Novo Nordisk A/S, Roche Holdings AG, PolyPeptide Group, Sanofi, 

Millennium Pharmaceuticals Inc., Teva Pharmaceutical Industries Ltd., and Takeda Pharmaceutical Co. Ltd. are the major 

enterprises working in the global peptide therapeutics industry. The market is mostly concentrated as Takeda, Teva, and 

Novo Nordisk collectively hold more than 50% of the overall peptide therapeutics market. 

The forthcoming patent expiry of Copaxone by Teva and Velcade by Millennium Pharma and the projected launch of their 

generic alternatives are expected to change the dynamics of the global peptide therapeutics market in the near future. 

Request a Brochure of this Report: http://www.transparencymarketresearch.com/sample/sample.php?flag=s&rep_id=418 

Table of Contents 


3


Chapter 1 Introduction 

1.1 Report Description 

1.2 Market Segmentation 

1.3 Research Methodology 

1.4 List of Abbreviations 

1.5 Assumptions and Stipulations 

Chapter 2 Executive Summary 

2.1 Market Snapshot: Global Peptide Therapeutics Market (2013 & 2020) 

2.2 Global Peptide Therapeutics Market, by Applications, 2013 (USD Million) 

Chapter 3 Global Peptide Therapeutics Market Overview 

3.1 Introduction 

3.2 Emerging Trends in Peptide Therapeutics Market 

3.2.1 Trends in Peptide Manufacturing Technology 

3.2.2 Trends in Peptide API Supply 

3.3 Market Dynamics 

3.3.1 Drivers 

3.3.1.1 Increase in cancer and diabetes patient population to propel the growth of new peptides 

3.3.1.2 Rich R&D pipeline of peptide drugs is expected to drive growth 

3.3.1.3 Technological advancements have reduced total production cost of peptides 

3.3.2 Restraints 

3.3.2.1 Increasing complexity of peptides is a huge challenge for API manufacturers 

3.3.2.2 Lack of regulatory standards 


4


3.3.3 Opportunities 

3.3.3.1 Generic peptides market to flourish with patent cliff expected during the forecast period 

3.3.3.2 Biotech firms collaborating with large pharmaceutical companies to explore further growth 

3.4 Regulatory Scenario 

3.5 Porter’s Five Forces Analysis: Global Peptide Therapeutics Market 

3.5.1 Bargaining Power of Suppliers 

3.5.2 Bargaining Power of Buyer 

3.5.3 Threat of Substitutes 

3.5.4 Threat of New Entrants 

3.5.5 Competitive Rivalry 

3.6 Event Impact Analysis 

3.6.1 Event Impact Analysis: Global Peptide Therapeutics Market 

3.7 Market Attractiveness Analysis 

3.7.1 Market Attractiveness Analysis of Global Peptide Therapeutics Market, by Geography, 2013 

3.8 Market Share Analysis 

Chapter 4 Global Peptide Therapeutics Market, by Applications 


4.1.1 Global Peptide Therapeutics Market Revenue, by Application, 2012 – 2020 (USD Million) 

4.2 Cancer 

4.2.1 Global Cancer Peptide Therapeutics Market Revenue, 2012 – 2020 (USD Million) 

4.2.2 Zoladex (goserelin) 

4.2.3 Velcade (bortezomib) 

4.2.4 Lupron/ Enantone/ Eligard (leuprorelin) 


5


4.2.5 Others 

4.3 Cardiovascular 

4.3.1 Global Cardiovascular Disorders Peptide Therapeutics Market Revenue, 2012 – 2020 (USD Million) 

4.3.2 Angiomax (bivalirudin) 

4.3.3 Integrilin (eptifibatide) 

4.4 Central Nervous System 

4.4.1 Global Central Nervous System Peptide Therapeutics Market Revenue, 2012 – 2020 (USD Million) 

4.4.2 Copaxone (glatiramer) 

4.5 Metabolic Disorders 

4.5.1 Global Metabolic Disorders Peptide Therapeutics Market Revenue, 2012 – 2020 (USD Million) 

4.5.2 Victoza (liraglutide) 

4.5.3 Byetta (exenatide) 

4.5.4 Others 

4.6 Infection 

4.6.1 Global Infection Peptide Therapeutics Market Revenue, 2012 – 2020 (USD Million) 

4.6.2 Incivek (telaprevir) 

4.6.3 Victrelis (boceprevir) 

4.7 Hematological Disorders 

4.7.1 Global Hematological Disorders Peptide Therapeutics Market Revenue, 2012 – 2020 (USD Million) 

4.7.2 Firazyr (icatibant) 

4.7.3 Kalbitor (ecallantide) 

4.8 Gastrointestinal Disorders 

4.8.1 Global Gastrointestinal Disorders Peptide Therapeutics Market Revenue, 2012 – 2020 (USD Million) 

4.8.2 Gattex (teduglutide) 


6


4.8.3 Linzess (linaclotide) 

4.9 Respiratory Disorders 

4.9.1 Global Respiratory Disorders Peptide Therapeutics Market Revenue, 2012 - 2020 (USD Million) 

4.10 Acromegaly 

4.10.1 Global Acromegaly Peptide Therapeutics Market Revenue, 2012 – 2020 (USD Million) 

4.11 Other Applications 

4.11.1 Global Other Applications Peptide Therapeutics market Revenue, 2012 - 2020 (USD Million) 

Chapter 5 Global Peptide Therapeutics Market, by Route of Administration 


5.1.1 Global Peptide Therapeutics Market Revenue, by Route of Administration, 2012 - 2020 (USD Million) 

5.2 Parenteral Route of Administration 

5.2.1 Global Peptide Therapeutics Market Revenue, by Parenteral Route of Administration, 2012 - 2020 (USD 

Million) 

5.3 Oral Route of Administration 

5.3.1 Global Peptide Therapeutics Market Revenue, by Oral Route of Administration, 2012 - 2020 (USD Million) 

Chapter 6 Global Peptide Therapeutics Market, by Marketing Status 


6.1.1 Global Peptide Therapeutics Market Revenue, by Marketing Status, 2012 - 2020 (USD Million) 

6.2 Branded Peptide Therapeutics 

6.2.1 Global Branded Peptide Therapeutics Market Revenue, 2012 - 2020 (USD Million) 

6.3 Generic Peptide Therapeutics 

6.3.1 Global Generic Peptide Therapeutics Market Revenue, 2012 - 2020 (USD Million) 


7


Chapter 7 Global Peptide Therapeutics Pipeline Overview 


7.1.1 Global Peptide Therapeutics Pipeline Overview 

Chapter 8 Global Peptide Therapeutics Market, by Geography 


8.1.1 Global Peptide Therapeutics Market Revenue, by Geography, 2012 - 2020 (USD Million) 

8.2 North America 

8.2.1 North America Peptide Therapeutics Market Revenue, 2012 - 2020 (USD Million) 

8.3 Europe 

8.3.1 Europe Peptide Therapeutics Market Revenue, 2012 - 2020 (USD Million) 

8.4 Asia Pacific 

8.4.1 Asia Pacific Peptide Therapeutics Market Revenue, 2012 - 2020 (USD Million) 

8.5 Rest of the World 

8.5.1 Rest of the World Peptide Therapeutics Market Revenue, 2012 - 2020 (USD Million) 

Chapter 9 Recommendations 

9.1 Rigorous research and development (R&D) would yield new products 

9.2 Facility expansion in emerging economies 

9.3 Rapid inorganic growth through acquisitions 

Chapter 10 Company Profiles 

10.1 Amgen, Inc. 


8


10.1.1 Company Overview 

10.1.2 Financial Overview 

10.1.3 Product Portfolio 

10.1.4 Business Strategies 

10.1.5 Recent Developments 

10.2 AstraZeneca plc 






10.3 Bachem Holding AG 






10.4 CordenPharma International GmbH 






10.5 Eli Lilly and Company 


9







10.6 Ipsen S.A. 






10.7 Lonza Group Ltd. 






10.8 Merck & Co., Inc. 






10.9 Novartis AG 


10







10.10 Novo Nordisk A/S 






10.11 PolyPeptide Group 






10.12 Roche Holdings AG 






10.13 Sanofi 


11







10.14 Takeda Pharmaceutical Company Limited 






10.15 Teva Pharmaceutical Industries Ltd. 






List of Figures 

FIG. 1 Peptide Therapeutics Market Segmentation 

FIG. 2 Global Peptide Therapeutics Market, by Applications, 2013 (USD Million) 

FIG. 3 Porter’s Five Forces Analysis: Global Peptide Therapeutics Market 

FIG. 4 

FIG. 5 Market Attractiveness Analysis of Global Peptide Therapeutics Market, by Geography, 2013 


12


FIG. 6 Market Share Analysis of Global Peptide Therapeutics Market, by Key Players, 2013 (Value %) 

FIG. 7 Global Central Nervous System Peptide Therapeutics Market Revenue, 2012 – 2020 (USD Million) 

FIG. 8 Global Respiratory Disorders Peptide Therapeutics Market Revenue, 2012 - 2020 (USD Million) 

FIG. 9 Global Other Applications Peptide Therapeutics Market Revenue, 2012 - 2020 (USD Million) 

FIG. 10 Global Peptide Therapeutics Market Revenue, by Parenteral Route of Administration, 2012 - 2020 (USD 

Million) 

FIG. 11 Global Peptide Therapeutics Market Revenue, by Oral Route of Administration, 2012 - 2020 (USD Million) 

FIG. 12 Global Branded Peptide Therapeutics Market Revenue, 2012 - 2020 (USD Million) 

FIG. 13 Global Generic Peptide Therapeutics Market Revenue, 2012 - 2020 (USD Million) 

FIG. 14 North America Peptide Therapeutics Market Revenue, 2012 - 2020 (USD Million) 

FIG. 15 Europe Peptide Therapeutics Market Revenue, 2012 - 2020 (USD Million) 

FIG. 16 Asia Pacific Peptide Therapeutics Market Revenue, 2012 - 2020 (USD Million) 

FIG. 17 Rest of the World Peptide Therapeutics Market Revenue, 2012 - 2020 (USD Million) 

FIG. 18 Amgen, Inc: Annual Revenue, 2011 – 2013 (USD Million) 

FIG. 19 AstraZeneca plc: Annual Revenue, 2011 – 2013 (USD Million) 

FIG. 20 Bachem Holding AG: Annual Revenue, 2011 – 2013 (USD Million) 

FIG. 21 Eli Lilly and Company: Annual Revenue, 2011 – 2013 (USD Million) 

FIG. 22 Ipsen S.A.: Annual Revenue, 2011 – 2013 (USD Million) 

FIG. 23 Lonza Group Ltd.: Annual Revenue, 2011 – 2013 (USD Million) 

FIG. 24 Merck & Co., Inc.: Annual Revenue, 2011 – 2013 (USD Million) 

FIG. 25 Novartis AG Annual Revenue: 2011 – 2013 (USD Million) 

FIG. 26 Novo Nordisk A/S Annual Revenue: 2011 – 2013 (USD Million) 

FIG. 27 Roche Holdings AG: Annual Revenue: 2011 – 2013 (USD Million) 

FIG. 28 Sanofi: Annual Revenue, 2011 – 2013 (USD Million) 


13


FIG. 29 Takeda Pharmaceutical Co. Ltd.: Annual Revenue: 2011 – 2013 (USD Million) 

FIG. 30 Teva Pharmaceutical Co. Ltd.: Annual Revenue: 2011 – 2013 (USD Million) 

List of Tables 

TABLE 1 Market Snapshot: Global Peptide Therapeutics Market (2013 & 2020) 

TABLE 2 Event Impact Analysis: Global Peptide Therapeutics Market 

TABLE 3 Global Peptide Therapeutics Market Revenue, by Application, 2012 – 2020 (USD Million) 

TABLE 4 Global Cancer Peptide Therapeutics Market Revenue, 2012 – 2020 (USD Million) 

TABLE 5 Global Cardiovascular Disorders Peptide Therapeutics Market Revenue, 2012 – 2020 (USD Million) 

TABLE 6 Global Metabolic Disorders Peptide Therapeutics Market Revenue, 2012 – 2020 (USD Million) 

TABLE 7 Global Infection Disorders Peptide Therapeutics Market Revenue, 2012 – 2020 (USD Million) 

TABLE 8 Global Hematological Disorders Peptide Therapeutics Market Revenue, 2012 – 2020 (USD Million) 

TABLE 9 Global Gastrointestinal Disorders Peptide Therapeutics Market Revenue, 2012 – 2020 (USD Million) 

TABLE 10 Global Acromegaly Peptide Therapeutics Market Revenue, 2012 – 2020 (USD Million) 

TABLE 11 Global Peptide Therapeutics Market Revenue, by Route of Administration, 2012 - 2020 (USD Million) 

TABLE 12 Global Peptide Therapeutics Market Revenue, by Marketing Status, 2012 - 2020 (USD Million) 

TABLE 13 Global Peptide Therapeutics Market Pipeline Overview 

TABLE 14 Global Peptide Therapeutics Market Revenue, by Geography, 2012 - 2020 (USD Million) 

About Us 

Transparency Market Research is a global market intelligence company, providing global business information 

reports and services. Our exclusive blend of quantitative forecasting and trends analysis provides forwardlooking 

insight for thousands of decision makers. We are privileged with a highly experienced team of Analysts, 

Researchers, and Consultants, who use proprietary data sources and various tools and techniques to gather, and 

analyze information. 


14


Our data repository is continuously updated and revised by a team of research experts, so that it always reflects 

the latest trends and information. With a broad research and analysis capability, Transparency Market Research 

employs rigorous primary and secondary research techniques in developing distinctive data sets and research 

material for business reports. 

Contact 

Mr.Nachiket 

90 State Street, 

Suite 700, 

Albany 

NY - 12207 

United States 

Tel: +1-518-618-1030 

USA - Canada Toll Free 866-552-3453 

Email: sales@transparencymarketresearch.com 

Website: http://www.transparencymarketresearch.com/ 


15

Global Peptide Therapeutics Market to be Fueled by Increasing Prevalence of Cancer and Diabetes

You also want an ePaper? Increase the reach of your titles

Delete template?

Save as template?